Meta tags:
keywords=;
description=;

Headings (most frequently used words):

you, about, to, exit, abbott, website, investors, newsroom, responsibility, careers, press, releases, are, for, another, country, or, region, specific, do, wish, continue, and, this, subscribe, consumers, healthcare, professionals, partners, contact, site, map, policies, privacy, policy, terms, conditions,

Text of the page (most frequently used words):
and (56), the (45), #screening (40), cologuard (36), #abbott (34), cancer (25), plus (19), colorectal (18), for (16), are (15), crc (15), tests (13), with (13), that (11), 2026 (10), noninvasive (9), both (9), acs (9), colonoscopy (8), test (8), guideline (8), loading (7), about (7), based (7), follow (7), who (7), more (7), options (7), this (6), have (6), may (6), not (6), outcomes (6), when (6), our (6), patient (6), first (6), preferred (6), overview (6), site (5), further (5), stool (5), adherence (5), from (5), healthcare (5), blood (5), patients (5), professionals (5), you (4), website (4), all (4), privacy (4), impact (4), specificity (4), which (4), people (4), performance (4), detection (4), line (4), recommended (4), cancers (4), press (4), responsibility (4), careers (4), faqs (4), medical (3), other (3), products (3), approved (3), specific (3), identify (3), services (3), health (3), data (3), policy (3), limburg (3), three (3), dna (3), exact (3), sciences (3), rates (3), 2021 (3), age (3), life (3), leading (3), than (3), risk (3), results (3), fda (3), high (3), designed (3), reduce (3), only (3), included (3), quality (3), guidelines (3), early (3), updated (3), strong (3), well (3), positioned (3), precancerous (3), lesions (3), used (3), will (3), support (3), share (3), content (3), releases (3), contact (3), consumers (3), subscribe (3), events (3), continue (2), exit (2), please (2), requested (2), country (2), region (2), information (2), devices (2), countries (2), also (2), product (2), trade (2), without (2), preferences (2), terms (2), conditions (2), policies (2), media (2), ebner (2), vahdat (2), estes (2), testing (2), one (2), med (2), doi (2), capacity (2), maximize (2), greene (2), real (2), world (2), payer (2), 2025 (2), res (2), united (2), states (2), corporation (2), madison (2), analysis (2), different (2), overall (2), preventive (2), task (2), force (2), weighted (2), population (2), xavier (2), llor (2), study (2), helps (2), portfolio (2), spectrum (2), diagnostics (2), serve (2), facebook (2), linkedin (2), molecular (2), sample (2), improving (2), through (2), helping (2), minimize (2), unnecessary (2), colonoscopies (2), precancer (2), adults (2), older (2), average (2), disease (2), allowing (2), kit (2), time (2), hedis (2), measures (2), prevention (2), approaches (2), said (2), established (2), across (2), help (2), close (2), improve (2), modeling (2), found (2), could (2), detect (2), mortality (2), years (2), over (2), initial (2), participation (2), million (2), navigation (2), program (2), year (2), interval (2), proven (2), new (2), approval (2), uniquely (2), seamless (2), expand (2), providers (2), treatable (2), removed (2), medicine (2), offer (2), additional (2), provider (2), american (2), society (2), reaffirms (2), leadership (2), newsroom (2), investors (2), glance (2), heritage (2), search (2), jobs (2), conferences (2), benefits (2), culture (2), students (2), working (2), news (2), yes, wish, aware, intended, residents, particular, noted, result, contain, pharmaceuticals, uses, those, regions, optimized, your, screen, size, another, unless, otherwise, specified, service, names, appearing, internet, trademarks, owned, licensed, its, subsidiaries, affiliates, use, any, trademark, name, dress, made, prior, written, authorization, except, company, rights, reserved, read, legal, notice, details, submit, eventtype, pageurl, advertising, myabbott, consumer, lindsey, dickinson, 608, 690, 0383, financial, michael, comilla, 224, 668, 1872, source, dore, ozbay, foster, model, evaluation, effectiveness, rounds, multitarget, versus, econ, 986, 993, 1080, 13696998, 2645491, fendrick, kurlander, gohil, lieberman, optimizing, 1016, gastha, 100930, gastro, hep, adv, stieber, lemaster, closing, loop, after, positive, sdna, fit, fobt, stratified, type, 1629, 1639, curr, opin, gohill, multi, target, int, dis, file, completed, 000581, finney, rutten, miller, wilson, trends, national, interview, survey, modalities, phila, 2024, 275, 280, prev, clinician, brochure, davidson, barry, mangione, recommendation, statement, 325, 1965, 1977, jama, including, participants, did, advanced, neoplasia, previously, served, principal, investigator, now, was, compensated, work, global, leader, live, fully, stages, changing, technologies, spans, businesses, nutritionals, branded, generic, medicines, 122, 000, colleagues, 160, connect, youtube, instagram, com, rely, exclusively, subjective, reported, factors, reducing, variability, accuracy, enabling, faster, building, success, features, novel, biomarkers, improved, laboratory, processes, enhanced, stability, likelihood, false, positives, demonstrate, commitment, access, developed, collaboration, mayo, clinic, aged, revolutionized, detecting, markers, associated, complete, collection, home, special, preparation, off, return, lab, uspstf, advocacy, organization, develops, evidence, inform, clinicians, policymakers, public, shape, practices, reinforces, importance, combine, clinical, ability, reach, paul, chief, officer, business, persistent, gaps, reinforced, peer, reviewed, studies, recently, published, approach, nearly, double, prevent, removal, related, costs, while, focus, therapeutic, procedures, separate, suggests, intervals, deliver, substantially, gained, single, these, were, driven, transformed, driving, estimated, nationwide, increase, 2018, 2014, been, times, supported, robust, demonstrated, category, needed, satisfaction, supporting, repeat, enters, era, broad, adoption, alongside, agreement, commercialize, freenome, pending, upon, launch, ordering, experience, among, individuals, decline, methods, drive, optimal, leverage, nexus, platform, date, highly, caught, survivable, cases, even, preventable, pre, but, still, eligible, americans, remain, unscreened, professor, director, pancreatic, yale, school, tools, like, allow, performing, cater, needs, increasing, chances, positively, impacting, incidence, devastating, most, can, during, detects, expected, confidence, backed, commercial, infrastructure, ensure, scale, reliability, experiences, such, stars, incentives, nyse, abt, today, announced, has, released, reaffirm, prnewswire, park, ill, recent, publications, strategy, demonstrating, better, systems, payers, aligned, recommendations, combining, reaffirmed, download, photos, twitter, back, map, partners, fund, sustainability, social, executive, team, experts, honors, contacts, governance, resources, stock, info, financials,

Text of the page (random words):
acs guideline reaffirms abbott leadership in noninvasive colorectal cancer screening may 27 2026 investors overview financials stock info resources news events governance newsroom news press releases press contacts honors experts executive team responsibility overview social impact sustainability abbott fund subscribe consumers consumers healthcare professionals healthcare professionals careers overview working with us professionals students our people and culture benefits faqs conferences events search jobs careers overview working with us professionals students our people and culture benefits faqs conferences events search jobs about abbott overview who we are our heritage abbott at a glance abbott faqs contact us responsibility subscribe about abbott overview who we are our heritage abbott at a glance abbott faqs contact us responsibility subscribe consumers healthcare professionals careers about abbott careers investors newsroom responsibility partners contact site map policies privacy policy terms conditions press releases back to press releases acs guideline reaffirms abbott leadership in noninvasive colorectal cancer screening share content to facebook share content to linkedin share content to twitter photos 1 may 27 2026 download hi res close cologuard and cologuard plus reaffirmed as preferred options for noninvasive colorectal cancer crc screening in updated american cancer society guideline abbott to offer only crc screening portfolio aligned to new acs recommendations combining preferred stool based plus additional blood based options recent publications support cologuard first strategy demonstrating better outcomes for patients providers health systems and payers abbott park ill may 27 2026 prnewswire abbott nyse abt today announced that the american cancer society acs has released updated colorectal cancer crc screening guidelines that reaffirm cologuard and cologuard plus as preferred noninvasive screening options for adults age 45 and older who are at average risk for crc both tests are used at a three year interval cologuard and cologuard plus are preferred u s preventive services task force recommended noninvasive screening tests designed to detect crc early when it is most treatable and identify precancerous lesions that can be removed during follow up colonoscopy 1 cologuard plus detects 95 of colorectal cancers at 94 specificity age weighted to the u s screening population which is expected to minimize unnecessary follow up colonoscopies and maximize confidence in results 2 both tests are backed by abbott s well established patient navigation support and commercial infrastructure to ensure scale reliability and seamless patient and provider experiences further both tests are included in colorectal cancer screening quality measures such as hedis and stars which support payer and provider quality incentives colorectal cancer is highly treatable when caught early survivable in about 90 of cases and is even preventable when pre cancers are found and removed but still up to 60 million eligible americans remain unscreened said dr xavier llor professor of medicine and director gi and pancreatic cancer prevention program yale school of medicine screening tools like cologuard and cologuard plus allow us to offer additional well performing options to cater to the needs of different patients increasing the chances at positively impacting incidence and mortality rates from this devastating disease in the united states abbott uniquely positioned to expand screening in line with acs guideline with the proven performance and broad adoption of cologuard and cologuard plus alongside abbott s agreement to commercialize a blood based test from freenome pending fda approval abbott is uniquely positioned across the spectrum of noninvasive crc screening upon approval abbott will launch the blood based test with a seamless ordering experience designed to expand participation among individuals who decline other screening methods cologuard tests will continue to serve as preferred first line screening options to help drive optimal outcomes both tests will leverage abbott s nexus platform which helps providers identify patients who are not up to date on crc screening and improve adherence over time proven crc screening impact of cologuard enters new era with cologuard plus cologuard tests have transformed colorectal cancer screening driving an estimated 77 of the nationwide increase in crc screening participation from 2018 to 2021 3 first included in the acs colorectal cancer screening guideline in 2014 the tests have been used more than 23 million times 4 supported by a robust patient navigation program cologuard tests have demonstrated strong real world adherence to initial screening 5 category leading follow up colonoscopy rates when needed 6 and high patient satisfaction 4 supporting repeat screening at the guideline recommended three year interval this impact is further reinforced by peer reviewed modeling studies one recently published analysis found that a cologuard first screening approach could nearly double crc detection prevent more cancers through the detection and removal of precancerous lesions and reduce crc related costs while allowing colonoscopy capacity to focus on follow up and therapeutic procedures 7 a separate modeling study suggests that cologuard plus when used at guideline recommended intervals could detect more cancers and precancerous lesions reduce mortality and deliver substantially more life years gained over 10 years than a single screening colonoscopy 8 these outcomes were driven by strong test performance and high adherence to both initial screening and follow up colonoscopy the updated acs guideline reinforces the importance of screening approaches that combine strong clinical performance with the ability to reach more patients said paul limburg m d chief medical officer screening abbott s cancer diagnostics business with cologuard and cologuard plus established as preferred first line screening options abbott is well positioned across both stool and blood based approaches to help close persistent screening gaps and improve outcomes in colorectal cancer acs is a leading cancer advocacy organization that develops evidence based guidelines to inform clinicians policymakers and the public helping shape cancer prevention screening and early detection practices about the cologuard and cologuard plus tests developed in collaboration with mayo clinic the cologuard and cologuard plus tests are first line noninvasive colorectal cancer crc screening options for adults aged 45 or older who are at average risk for the disease the cologuard test revolutionized crc screening by detecting specific dna markers and blood in stool associated with cancer and precancer allowing patients to complete the collection kit at home without special preparation or time off and return the kit to the lab for results it is also the only noninvasive molecular crc screening test recommended by uspstf 2021 and both cologuard and cologuard plus are included in hedis quality measures and the acs guidelines 2026 building on this success the fda approved cologuard plus test features novel biomarkers improved laboratory processes and enhanced sample stability through high performance the cologuard plus test is designed to reduce the likelihood of false positives helping to minimize unnecessary follow up colonoscopies further cologuard plus is the only noninvasive test fda approved for both cancer and precancer detection both tests demonstrate abbott s commitment to improving crc screening access and outcomes cologuard and cologuard plus rely exclusively on molecular data from the patient sample not subjective patient reported risk factors reducing variability improving accuracy and enabling faster results about abbott abbott is a global healthcare leader that helps people live more fully at all stages of life our portfolio of life changing technologies spans the spectrum of healthcare with leading businesses and products in diagnostics medical devices nutritionals and branded generic medicines our 122 000 colleagues serve people in more than 160 countries connect with us at abbott com and on linkedin facebook instagram x and youtube 94 specificity when age weighted to the u s screening population cologuard plus specificity 91 overall specificity including all participants who did not have advanced neoplasia dr xavier llor previously served as a principal investigator on a study with exact sciences which is now abbott he was not compensated for media work davidson kw barry mj mangione cm et al screening for colorectal cancer us preventive services task force recommendation statement jama 2021 325 19 1965 1977 cologuard plus clinician brochure madison wi exact sciences corporation ebner dw finney rutten lj miller wilson la et al trends in colorectal cancer screening from the national health interview survey analysis of the impact of different modalities on overall screening rates cancer prev re s phila 2024 17 6 275 280 data on file exact sciences corporation madison wi cologuard tests completed cl 000581 2026 le qa greene m gohill s et al adherence to multi target stool dna testing for colorectal cancer screening in the united states int j colorectal dis 2025 40 16 greene m stieber b lemaster jw et al closing the loop in colorectal cancer screening real world adherence to follow up colonoscopy after positive mt sdna vs fit fobt stratified by payer type curr med res opin 2025 41 9 1629 1639 fendrick am kurlander je vahdat v estes c gohil s limburg pj lieberman da optimizing colonoscopy capacity to maximize colorectal cancer outcomes gastro hep adv 2026 doi 10 1016 j gastha 2026 100930 dore m ebner dw vahdat v estes c ozbay ab foster v limburg pj model based evaluation of colorectal cancer screening effectiveness three rounds of multitarget stool dna testing versus one colonoscopy j med econ 2026 29 1 986 993 doi 10 1080 13696998 2026 2645491 source abbott for further information abbott media lindsey dickinson 608 690 0383 abbott financial michael comilla 224 668 1872 policies terms conditions privacy policy consumer health data privacy policy myabbott privacy preferences advertising preferences pageurl eventtype submit 2026 abbott all rights reserved please read the legal notice for further details unless otherwise specified all product and service names appearing in this internet site are trademarks owned by or licensed to abbott its subsidiaries or affiliates no use of any abbott trademark trade name or trade dress in this site may be made without the prior written authorization of abbott except to identify the product or services of the company you are about to exit for another abbott country or region specific website please be aware that the website you have requested is intended for the residents of a particular country or region as noted on that site as a result the site may contain information on pharmaceuticals medical devices and other products or uses of those products that are not approved in other countries or regions the website you have requested also may not be optimized for your specific screen size do you wish to continue and exit this website yes no loading loading loading loading loading loading loading